MF
Conditions
Brief summary
This trial adopts a multicenter, open label, positive drug parallel controlled clinical trial design, with a planned enrollment of approximately 105 participants in the MF trial. Successful trial participants were selected and assigned to either the experimental group or the control group in a 2:1 stratified manner, with the stratification factor being the Dynamic International Prognostic Scoring System (DIPSS) prognostic grading criteria. Continuously take the test drug/control drug until it meets the withdrawal criteria.
Interventions
DRUGFlonoltinib 75mg
Flonoltinib 75mg，qd
Ruxolitinib Phosphate ,control group
Sponsors
Chengdu Zenitar Biomedical Technology Co., Ltd
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
1. Age range of 18-80 years old (including threshold), gender not limited; 2. Patients diagnosed with primary myelofibrosis (PMF) according to WHO criteria (2016 edition) or patients diagnosed with post polycythemia vera myelofibrosis (PPV-MF) or post thrombocytopenia myelofibrosis (PET-MF) according to IWG-MRT criteria; 3. Expected survival period greater than 24 weeks; 4. ECOG score 0-2 points; 5. Splenomegaly: Palpation of the splenic margin reaching or exceeding 5cm below the rib (distance from the intersection of the left clavicle midline and left rib margin to the farthest point of the spleen); Or due to physical reasons (such as obesity), it may not be palpable, but MRI/CT spleen evaluation during screening confirms a volume of \>= 450 cm\^3; 6. Within 7 days prior to randomization, the main organ functions were generally normal, meeting the following criteria: ALT and AST \<= 2.5 × ULN; TBIL\<=2.0×ULN； Serum creatinine \<=1.5 × ULN or serum creatinine clearance rate (Ccr)\>50 mL/min; INR, PT, and APTT \<= 1.5 × ULN; 7. Can understand and voluntarily sign an informed consent form.
Exclusion criteria
1. The toxic reactions of previous anti-cancer treatments have not recovered to grade 1 or below (excluding hair loss), or have not fully recovered from previous surgeries; 2. Allergy to experimental drugs and their excipients; 3. For any significant clinical and laboratory abnormalities, the researchers believe that they affect the safety evaluators, such as: a. uncontrollable diabetes - fasting blood glucose\>250 mg/dL (13.9 mmol/L), b. hypertension and cannot be reduced to the following range after treatment with two or more antihypertensive drugs (systolic blood pressure\<160 mmHg, diastolic blood pressure\<100 mmHg), c. peripheral neuropathy; 4. Patients with a history of congestive heart failure (NYHA grade III or above), unstable angina or myocardial infarction, cerebrovascular accidents or thromboembolism within the first 6 months of screening; 5. Individuals with impaired cardiac function (those with ejection fraction\<45% detected by echocardiography, congenital ventricular arrhythmia, QTcF\>450 ms on electrocardiogram (males), QTcF\>470 ms on electrocardiogram (females), or those with arrhythmia requiring treatment at the time of screening); 6. Patients with congenital or acquired bleeding disorders or unstable thrombotic diseases requiring anticoagulant therapy; 7. Any active infection requiring systemic treatment (oral, intravenous, subcutaneous, intramuscular, etc.) within the first 14 days of randomization; 8. Active infection of hepatitis B virus (HBV) or hepatitis C virus (HCV), except for the following patients: a) HBV infection: patients who are positive for hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb) and undergo peripheral blood HBV-DNA testing, with the lower limit of HBV-DNA detection value (i.e. the upper limit of normal value in the laboratory of each research center) can be enrolled; If the baseline HBsAg is positive, continuous antiviral treatment is required after enrollment, and HBV-DNA testing should be conducted every 12 weeks and at EOT visits; b) Patients who are positive for HCV serology but negative for HCV-RNA can be included in the study; 9. Patients who are positive for human immunodeficiency virus antibodies (HIV Ab) or anti Treponema pallidum antibodies (TP Ab) (Treponema pallidum antibodies positive); 10. Patients with epilepsy or those taking psychotropic or sedative drugs during screening; 11. Pregnant or lactating female patients, female/male patients with fertility who refuse to use contraceptive measures during the trial period and within 6 months after the trial ends; 12. Patients who have suffered from other malignant tumors within the past 5 years before the first administration (excluding cured carcinoma in situ and basal cell carcinoma of the skin); 13. Patients with combined swallowing difficulties; 14. Patients who participated in clinical trials of other new drugs or medical devices within the first month of randomization and took the study drug or used the study device; 15. Researchers believe that there are other factors that are not suitable for participating in the experiment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Percentage of subjects with >=35% reduction in spleen volume from baseline | Week 24 |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Spleen response time: The time when the spleen volume is first observed to decrease by >=35% from baseline | Week 12,week 24 | — |
| MPN-SAF TSS Total Symptom Score and Baseline Comparison Decrease | Week 2,week 4,week 8,week 12,week 24 | The MPN-SAF-TSS is used to assess the symptom burden of patients with myeloproliferative neoplasms. The questionnaire also reflects the quality of life of patients to a certain extent. During the diagnosis and treatment process, the MPN-10 questionnaire includes 10 sub symptoms (fatigue, early satiety, abdominal discomfort, poor activity, lack of concentration, night sweats, skin itching, bone pain, fever, and weight loss). Each item is graded from 0 (none) to 10 (heaviest), with a total score of 0-100 points. The higher the total score, the heavier the symptom burden. |
| Overall survival period | Week 2,week 4,week 8,week 12,week 24 | The time interval between the first use of medication and death caused by any reason |
Countries
China
Contacts
CONTACTWang Fangmei
CONTACTSun Liangkun
PRINCIPAL_INVESTIGATORXiao Zhijian, Doctor
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences (IHCAMS)
PRINCIPAL_INVESTIGATORNiu Ting, Doctor
West China Hospital
PRINCIPAL_INVESTIGATORMiao Jia, Doctor
West China Hospital
Outcome results
None listed